FDA approves first-line immunotherapy for patients with MSI-H/dMMR metastatic colorectal cancer
The U.S. Food and Drug Administration (FDA) approved pembrolizumab for intravenous injection for the first-line…
Browsing: mismatch repair deficient colorectal cancer